Search
Grace Therapeutics, Inc
GRCEAdd to Watchlist
2.240USD
-0.030-1.32%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
36.45MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Grace Therapeutics, Inc is 8.00, ranking 166 out of 387 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 11.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+164.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Grace Therapeutics, Inc
GRCE
2
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Grace Therapeutics, Inc's price target?
Analysts forecast that Grace Therapeutics, Inc's price target is USD 12.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 11.00.
How have Grace Therapeutics, IncGRCE's recent earnings per share performed?
The market expectation was USD -0.07, while Grace Therapeutics, IncGRCE's earnings per share (EPS) for the previous quarter was USD -0.14. EPS for the next quarter is expected at USD -0.15.
What is the analyst rating for Grace Therapeutics, Inc?
Based on the ratings of Grace Therapeutics, Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.